New approaches to antiglaucoma therapy.
Sugrue
M F
MF
Merck Research Laboratories, West Point, Pennsylvania 19486, USA. michael_sugrue@merck.com
D000241:Adenosine / Q000819:agonists / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002186:Cannabinoids / Q000737:chemistry / Q000627:therapeutic use; D015195:Drug Design; D016232:Endothelins / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006162:Guanylate Cyclase / Q000378:metabolism; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D018696:Neuroprotective Agents / Q000737:chemistry / Q000627:therapeutic use
D000959:Antihypertensive Agents; D002186:Cannabinoids; D016232:Endothelins; D018696:Neuroprotective Agents; D006162:Guanylate Cyclase; D000241:Adenosine